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Abstract
Food allergy is increasing in prevalence; as a result, there is intense focus on developing safe and 
effective therapies. Current methods of specific immunotherapy include oral, sublingual, and 
epicutaneous, while nonspecific methods that have been investigated include: Chinese herbal 
medicine, probiotics, and anti-IgE antibodies. Although some studies have demonstrated efficacy 
in inducing desensitization, questions regarding safety and the potential for achieving immune 
tolerance remain. Although some of these therapies demonstrate promise, further investigation is 
required before their incorporation into routine clinical practice.
Introduction
The increase in food allergy in the United States and throughout the world is a growing 
public health concern. From 1997 to 2007, the prevalence of food allergy in children 
increased by 18%.1 An estimated 15 million Americans have a food allergy, accounting for 
approximately 8% of children and 5% of adults.2 Although most reactions from accidental 
ingestions are typically mild and self-limited, severe cases of anaphylaxis are associated 
with peanut, tree nuts, and shellfish and have resulted in fatalities.3 Appropriately, there has 
Corresponding author: Bruce J. Lanser 1400 Jackson Street, J322, Denver, CO 80206. lanserb@njhealth.org. 
Disclosure Statement: B.J. Lanser, K.A. Orgel, and B.P. Vickery have nothing to disclose.
HHS Public Access
Author manuscript
Pediatr Clin North Am. Author manuscript; available in PMC 2016 August 02.
Published in final edited form as:













been an increase in research for food allergy treatments. Current guidelines for food allergy 
management include education, strict avoidance, nutritional monitoring, appropriate 
treatment of anaphylaxis with injectable epinephrine, and regular follow-up with an allergy 
specialist.4 In this review, the authors seek to update the previous article on food allergy 
therapy from this series, highlighting key clinical trials and emerging approaches for the 
treatment of food allergies.5
Standard of care
At present, there is no cure for food allergy. Diagnosis and management are focused on 
identification of triggers and targeted dietary elimination.4 Patients are encouraged to read 
ingredient labels, avoid cross-contamination, and consult with a nutritionist to ensure 
adequate growth. They are taught to recognize anaphylaxis and administer injectable 
epinephrine. In principle, strict dietary elimination should protect an individual from 
immunoglobulin (Ig) E–mediated reactions; however, in practice, patients with food allergies 
experience multiple exposures following diagnosis from both accidental and nonaccidental 
ingestions.67 Constant vigilance and perpetual risk produce significant anxiety. Quality-of-
life surveys among children with food allergies and their parents suggest this anxiety leads 
to restriction of daily activities.89 Avoidance measures can also result in nutritional deficits 
and growth impairment.10
Immunotherapy background
Oral immunotherapy (OIT) is not conceptually new, as instructions for treatment of egg 
sensitivity with egg white are recorded in the Babylonian Talmud.11 There are reports of 
physicians attempting food desensitization published as early as 1905 with varied success 
(Table 1). Investigators demonstrated that patients were able to tolerate foods after a period 
of gradual incremental exposure, usually occurring over a period of months to years.12 
Clinical texts through the mid-twentieth century reference hyposensitization to foods as a 
treatment for food allergy, although its effectiveness remained in question. In the 1980s, 
European investigators renewed interest in OIT after publishing positive results from small 
case series.1314 These early reports and studies paved the way for more systematic 
investigation of immunotherapy as an active treatment for food allergy. An understanding of 
the pathogenesis of IgE-mediated disease and mechanisms of desensitization has elucidated 
pathways for targeted approach. Interestingly, many questions raised by early investigators 
continue to elude researchers today (Box 1).
Immunotherapy mechanisms
Immunotherapy is based on the principle that incremental exposure to a given antigen can 
render an individual temporarily less reactive to that antigen (eg, desensitization) and 
eventually result in longer-lasting changes. Although the exact mechanisms are unknown, 
some of the immunologic changes that occur have been elucidated (Fig. 1).23 Early on, 
repeated administration of increasing immunotherapy doses suppressed basophil and mast 
cell reactivity. Interleukin-10 is produced, presumably by lymphocytes, which is thought to 
suppress allergic responses and drive production of IgG4 antibody. Initially, immunotherapy 
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increased the production of antigen-specific IgA, IgG1, IgG4, and IgE, although IgE tends 
eventually to decline to below baseline values in response to therapy (around 12–18 
months). Ultimately, these changes result in a decrease in tissue mast cells and eosinophils, 
accounting for clinical hyporesponsiveness to antigen exposure and diminished skin prick 
test reactivity.
Desensitization versus tolerance
Interpretation of food allergy literature requires understanding of an important distinction 
between the concepts of clinical desensitization and tolerance. Desensitization refers to a 
reversible state induced by short-term exposure to an allergen. Once administration of the 
allergen is discontinued, the previous level of clinical reactivity returns. An analogy would 
be the brief desensitization protocols widely used to manage patients with certain drug 
allergies. On the other hand, therapeutic tolerance would suggest that the immunotherapy 
treatment has induced disease-modifying changes that will persist even after the treatment is 
discontinued. Importantly, some individuals, regardless of treatment, will spontaneously 
develop immune tolerance and naturally outgrow their food sensitivity. Although eventual 
tolerance to milk and egg are relatively common, peanut, tree nut, and seafood allergies tend 
to persist over time.2
Incomplete understanding of the immunologic changes induced by immunotherapy, and 
whether these changes truly reflect immune tolerance, has led to the emergence of the term 
sustained unresponsiveness (SU). SU refers to the ability to successfully consume the treated 
allergen during an oral food challenge (OFC) performed typically 1 to 4 weeks after 
stopping active treatment. Importantly, many of the studies addressed in this review have 
only measured desensitization as a primary outcome. Only a few trials have addressed 
whether OIT results in SU, and none have done so in a rigorous, placebo-controlled 
fashion.23
Oral immunotherapy
Milk, egg, and peanut are the most studied foods in OIT trials. Most modern studies have 
been single-food OIT trials; as a result, these 3 major foods will be discussed separately. 
Overall, OIT trials have a dropout rate of 15% to 20%.24 Moreover, several studies have 
observed spontaneous resolution of food allergy among subjects receiving placebo. This 
finding is consistent with observational studies of the natural history of peanut allergy, for 
example, which have found spontaneous resolution in about 20% of individuals.25
General conclusions regarding efficacy are difficult to draw from the current literature 
because success rates for OIT have been defined differently. Ideally, subjects completing a 
course of immunotherapy should be able to incorporate culprit foods into their diets, 
consuming them ad libitum without symptoms. However, most studies only approximate the 
inclusion of the culprit food ad libitum in subjects’ diets. Studies often define success in 
terms of reaching a target maintenance dose or passing an endpoint challenge; therefore, it is 
important to interpret results in the context of the selected outcome measures. Overall safety 
of immunotherapy is also somewhat variable among studies, with adverse events not always 
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being categorized in the same way (eg, many exclude oral itching). The lack of natural 
history or control groups as comparisons in many studies has also limited the determination 
of safety. Safety and efficacy are discussed further with regards to specific studies.
In addition to significant heterogeneity and varied primary endpoints, published trials have 
other scientific shortcomings. Most clinical protocols incorporate a crossover design that 
allows subjects in the placebo group to be reassigned to the treatment arm after a 
desensitization challenge. Although this may facilitate subject recruitment and retention and 
satisfy ethical concerns associated with repeatedly challenging subjects treated with placebo, 
it does not allow for comparisons between subjects who successfully complete 
immunotherapy and those who might have developed natural tolerance. Table 2 provides a 
general overview of study design for OIT.
Despite the paucity of data supporting tolerance induction, some argue that OIT protects 
against accidental ingestions and improves quality of life, thus justifying its incorporation 
into clinical practice.2627 It is clear from multiple studies that OIT increases reaction 
thresholds, but there are no good data to prove this protects from reactions due to accidental 
ingestions. OIT has also not been thoroughly studied in subjects who are the most sensitive. 
A history of severe anaphylaxis is often a criterion for exclusion, while these patients might 
benefit the most from food immunotherapy.
Milk
Cow’s milk (CM) is the most common food allergy in early childhood. It is also one of the 
most important foods to reintroduce into the diets of children with food allergies, because 
children who must avoid milk are at an increased risk for significantly decreased weight, 
height, and body mass index–for-age percentiles.2829 A recent systematic review and meta-
analysis examined 6 randomized, controlled trials conducted between 2007 and 2012. 
Pooled data demonstrated a 10-fold increased likelihood of achieving desensitization to CM 
in children undergoing CM OIT than in non-OIT-treated patients. Subjects with CM allergy 
who underwent milk OIT tended to tolerate more milk protein, although these data did not 
reach statistical significance. A wide range of children received treatment with epinephrine 
during OIT trials (6.7%–30.8% of children); however, most reactions were mild.30
Maintenance of desensitization after CM OIT has been evaluated in 2 recent studies. A study 
published in 2013 evaluated 2 different CM maintenance regimens. Thirty-two children with 
milk allergy were randomized after successfully completing CM OIT and achieving 
desensitization, defined as consumption of 200 mL of CM. For 1 year, 16 patients continued 
daily maintenance ingestion of 150 to 200 mL of CM (group A), while the other 16 ingested 
the same amount twice weekly (group B). Both groups were also allowed to consume CM ad 
libitum. The primary outcome was maintenance of desensitization without symptoms on CM 
ingestion. Three subjects were lost to follow-up (1 in group A and 2 in group B). Adverse 
events were similar between groups, and none discontinued therapy due to adverse events or 
noncompliance. The authors concluded that twice-weekly ingestion of a maintenance dose 
seems to be equally effective at safely maintaining desensitization as the daily regimen, with 
9 of 15 subjects in group A and 9 of 15 subjects in group B consuming CM without 
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symptoms. It is important to note the absence of a placebo group or a group exclusively 
consuming CM ad libitum. Moreover, differences in the quantity of CM consumed ad 
libitum between groups were not assessed.31
In contrast, a retrospective study examined 32 patients who had successfully completed CM 
OIT under 2 different protocols (16 from each), with follow-up ranging from 1.3 to 5.3 
years. Twenty-two percent of subjects limited their consumption of CM due to symptoms, 
and only 31% of subjects tolerated full servings of CM with minimal or no symptoms. One 
subject required multiple doses of epinephrine for ongoing symptoms. Both studies provide 
important data that must be considered before starting OIT. Strict adherence to daily 
maintenance dosing may be difficult for children and families for a variety of reasons (eg, 
illness, travel, strenuous exercise, menses, food aversion). The same may be true for regular 
incorporation of trigger foods after OIT. It is also clear from these data that satisfactory 
long-term outcomes after CM immunotherapy appear to be dependent on ongoing exposure, 
which is difficult for some individuals. Importantly, some subjects who had been classified 
as protocol-defined successes in the trial seemed to have relapsed completely.32
Egg
In 2012, a multicenter study by the Consortium for Food Allergy Research (CoFAR) 
randomized 55 subjects with egg allergy (placebo 15, treatment 40). After 22 months of OIT 
using a daily maintenance dose of 2 g of egg white powder, 30 subjects (75%) passed a 
desensitization challenge (10 g of egg powder). After 6 to 8 weeks off treatment, just 11 of 
29 subjects tolerated this same amount of egg. Using intention-to-treat analysis, 28% had 
developed SU. This study revealed differences in rates of desensitization after OIT for 10 
months (55% passed a 5-g challenge) and 22 months (75% passed a 10-g challenge), 
suggesting that continued allergen administration over a prolonged period might improve 
efficacy. None of the subjects in the placebo arm passed the challenge at 10 months.33 In a 
more recent, smaller open trial of egg OIT, Meglio and colleagues34 achieved desensitization 
rates of 80% (8/10, active treatment) versus 20% (2/10, placebo) after 6 to 9 months of OIT.
A 2014 Cochrane Review analyzed 4 randomized, controlled trials of egg OIT. Only the 
CoFAR trial mentioned earlier included a placebo arm, whereas the other 3 compared 
subjects on OIT versus standard avoidance diet. Of the 100 patients receiving OIT in the 4 
studies, 69% experienced adverse events, with 5% requiring epinephrine. Overall, 44% 
could tolerate a partial serving of egg, while 39% could tolerate a whole egg. However, 
because of the small sample size, low quality of evidence, and methodological differences, 
the only conclusion that could be drawn was that desensitization seems to be possible in a 
large number of egg-allergic patients, but adverse events remain a significant concern.35
Peanut
Although less common than milk and egg allergy, peanut allergy is less likely to resolve 
spontaneously; as a result, it may be easier to study the effects of treatment in peanut-
allergic subjects. The only double-blind, placebo-controlled (DBPC) trial of OIT for peanut 
allergy was conducted in 2011 and assessed desensitization. Twenty-eight subjects (ages 1–
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16) were randomized to receive peanut OIT (n = 19) or placebo (n = 9). Three subjects 
(16%) in the OIT group discontinued treatment because of side effects, but all remaining 
participants tolerated a maintenance dose of 4000 mg of peanut protein and completed 12 
months of therapy. Each of the treatment subjects passed an OFC with 5000 mg of peanut 
protein after 1 year of therapy, compared with 280 mg in the placebo group (range, 0–1900 
mg; P <.001).36
The first study to investigate SU to peanut was published in 2014. In this open, non-placebo-
controlled trial of peanut OIT, 24 of 39 (61.5%) subjects completed therapy for up to 5 
years. Of these 24, 12 (50% per protocol, and 31% by intention to treat) were able to 
consume 5000 mg of peanut protein and 8000 to 10,000 mg of peanut butter after stopping 
OIT for 4 weeks. Thus, 12 patients were considered to achieve SU. These patients were 
subsequently instructed to incorporate peanut into their diet ad libitum at least several days 
per week. Questionnaire follow-up completed by 87.5% of the SU patients revealed that 
none experienced any allergic reactions due to peanut exposure, with a median follow-up 
time of 40 months.37
Another study in 2014 evaluated immunologic parameters and the possibility of SU to 
peanut after OIT or SLIT. Gorelik and colleagues38 found a greater effect for OIT than SLIT, 
but both demonstrated suppression of basophil activity and decreased Th2 responses to 
peanut. However, these changes were not preserved in some patients while on maintenance 
and waned in others after stopping immunotherapy. Despite the lack of a placebo group and 
its crossover design, the data strongly suggest that immunologic changes associated with SU 
may not be truly sustained in most patients.
The recent STOP II trial conducted in the United Kingdom was a 2-phase, randomized, 
controlled crossover trial of 99 children with peanut allergy (ages 7–16). During phase I, 
subjects were allocated to active treatment (n = 49) or elimination (n = 50). After an OFC at 
6 months, placebo subjects were reallocated to the treatment arm for phase II. The primary 
outcome measure of the study was the proportion of subjects able to tolerate 1400 mg of 
peanut protein following 6 months of OIT with 800 mg of peanut protein daily. Despite the 
lower maximum daily dose than that used in other OIT trials, 62% (24/39) of the treatment 
group was able to tolerate 1400 mg of peanut protein (approximately 10 peanuts) and were 
considered to be desensitized, while none of the placebo group passed the OFC. By the end 
of phase II, however, 84% of the active group and 91% of the control group were able to 
tolerate the daily maintenance doses. The study did not have participants stop OIT and thus 
did not assess for SU. Adverse reactions were higher in the treatment group as expected, 
although they were mild, primarily consisting of oral pruritus and abdominal pain.39
The findings described have led some clinicians to incorporate OIT into routine clinical 
practice.40 A retrospective chart review of peanut OIT used in clinical practice, not as 
research, following different protocols in multiple clinical sites was recently published. 
Results for 352 patients showed that 85% reached maintenance dosing, but actual dose and 
length of maintenance therapy differed by site. The authors argue that OIT is safe for use in 
clinical practice given the low rate of epinephrine administration (0.7 per 1000 escalation 
doses, 0.2 per 1000 maintenance doses). However, other adverse reactions were not reported, 
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and there is no evidence that accidental exposures were reduced or any other benefits were 
achieved.41 In addition, other studies have reported significantly higher rates of allergic 
reactions among OIT participants compared with those avoiding the food.42 Quality-of-life 
changes with OIT have also not been significantly observed, despite the assumption of 
improved quality of life with OIT. The Food Allergy Quality of Life Questionnaire was used 
before and after egg OIT in 22 children and their parents. They found only minimal 
improvement in health-related quality of life as rated by the parents, whereas children 
reported a benefit in terms of dietary restriction, but a negative impact by allergic reactions 
due to OIT.43 More data conclusively demonstrating safety and efficacy are needed in order 
to justify routine clinical use of OIT outside of a research setting.44
Extensively heated milk and egg as oral immunotherapy
Baking egg or milk proteins decreases their allergenicity, likely due to alteration of 
conformational epitopes. However, heating alone does not reduce the allergenicity of all 
proteins; in fact, with limited heat application, some foods can form neoepitopes, increasing 
their allergenicity.45 Baking food proteins with wheat may also confer a matrix effect in 
which the wheat-protein complex alters sequential IgE-binding epitopes that are unaffected 
by heat alone. This decreased allergenicity is sufficient for many patients to tolerate the 
trigger food on a regular basis.46 There is evidence to suggest that regular consumption of 
baked egg- and milk-containing products may help patients outgrow these allergies more 
quickly, although this evidence is weakened by the lack of an appropriate control group. 
Several studies have demonstrated that regular ingestion of baked egg or milk may hasten 
and increase rates of SU to nonbaked egg or milk when compared with strict avoidance. 
These studies have also shown that consumption of baked egg or milk decreases skin prick 
test size and increases IgG4. As seen in OIT, specific IgE increases initially and ultimately 
decreases with time. Although tolerance to baked goods may be associated with a milder 
clinical phenotype, these data suggest that introduction of baked allergens may actually alter 
the natural history of egg and milk allergies.47
Introduction of baked egg or milk into the diets of allergic children should be performed 
cautiously. Although some studies suggest that some patients can perform these OFCs at 
home, passage rates range from 60%48 to 85%, and up to 20% of failures to baked egg 
require epinephrine.49 Ideally, patients should be evaluated by an allergist and undergo a 
medically supervised OFC before introducing baked allergens.
Multiple food oral immunotherapy
Although OIT for single allergens shows promise, up to 30% of children with food allergy 
are sensitive to more than one allergen50 and in highly atopic populations, this proportion 
may be greater than 50%.51 Results from a phase I trial of multifood OIT were recently 
published. Forty participants (ages 4–46) were recruited, and a DBPC OFC to peanut was 
performed at enrollment. Additional reported food allergies were documented with 
subsequent DBPC OFCs. Twenty-five subjects were started on multifood OIT after 
demonstrating 1 or more food allergies in addition to peanut allergy. The remaining 15 
subjects were diagnosed with peanut allergy alone and allocated to single allergen OIT. 
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Doses of each allergen were escalated until a maintenance dose of 4000 mg was reached. 
Adverse reaction rates did not differ significantly between groups, and the dropout rates 
were similar. Two subjects from each group required treatment with epinephrine for OIT 
dose-related reactions.52 This study suggests the safety of multifood OIT is comparable to 
peanut OIT, but further randomized trials are needed to demonstrate efficacy.
Sublingual immunotherapy
The first study evaluating food SLIT was performed in Europe for hazelnut allergy. SLIT for 
pollen allergy had been widely used in Europe before this study, and the US Food and Drug 
Administration (FDA) recently approved its use with tablets for grass and ragweed allergies 
(dust mite remains in development). Like OIT, SLIT takes advantage of allergen exposure 
through the oral mucosa, which is thought to be tolerogenic. Liquid doses are delivered to 
the surface under the tongue, where antigen-presenting cells (ie, Langerhans cells) take up 
the antigen.53 Extract concentrations and the volume of liquid that can be held under a 
patient’s tongue have limited the utility of SLIT. Unlike OIT doses that range from 
milligrams to grams, SLIT doses typically range from micrograms to milligrams at 
maintenance. Although the quantity of antigen delivered is smaller with SLIT, the oral 
mucosa is exposed to undigested antigen, in contrast to OIT, which exposes the antigen to 
gastric digestion.54 Clinical trials investigating the safety and efficacy of SLIT in the 
treatment of food allergies have been limited to studies on hazelnut55 and peach allergy,56 
which is not reviewed here, as well as milk and peanut, that are discussed later.
Results of DBPC, randomized trials examining the use of SLIT in peanut allergy have been 
published. In 2011, Kim and colleagues57 published a study in which 18 children (ages 1–
11) completed 12 months of dosing followed by a DBPC OFC. Eleven subjects were 
randomized to active treatment with peanut with a goal dose of 2500μg daily, while 7 
subjects were randomized to placebo. Compliance was similar between the groups, with 
only 0.26% of peanut doses requiring treatment with antihistamines and 0.02% of home 
doses requiring albuterol for minor wheeze. The median cumulative tolerated dose after 1 
year of SLIT therapy in the peanut group was 1710 mg of peanut protein, compared with 85 
mg for the placebo group.
The largest published SLIT study was performed in 40 peanut-allergic subjects (ages 12–37 
years) by the CoFAR group in 2013. The first phase was a randomized, DBPC study for the 
first 44 weeks using a daily dose of 1386μg. After 44 weeks of therapy, subjects completed a 
5 g DBPC OFC to peanut. No subjects were able to consume the full 5 g of peanut powder 
(~50% peanut protein), but 14 (70%) peanut SLIT subjects were able to consume at least 10-
fold more peanut powder than at baseline (responders), compared with 3 (15%) placebo 
SLIT subjects. In the second phase, the placebo group crossed over to active treatment to a 
higher daily dose of peanut SLIT of 3696μg. This group completed a subsequent crossover 5 
g DBPC OFC after 44 weeks. At this challenge, 7 of the 16 (44%) subjects who crossed over 
to active treatment were considered responders. After 68 weeks of treatment in the original 
active peanut SLIT group, the median successfully consumed dose increased from 496 mg at 
44 weeks to 996 mg (P = .05); 5 subjects were able to consume the full 5 g, with one subject 
consuming 10 g, suggesting that longer-term therapy may confer increased dose threshold. 
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There was a high dropout rate among the 40 children, but this was largely due to personal 
reasons rather than side effects. In the first phase, 40.1% of peanut SLIT doses resulted in 
mild symptoms, but this decreased to 3.3% when oropharyngeal reactions were excluded. 
One subject on peanut SLIT in phase 1 did require epinephrine during up-dosing and was 
withdrawn from active therapy. Side effects were similar after crossover: 35.8% of doses 
after week 44 elicited symptoms, but only 1.1% of doses elicited symptoms when 
oropharyngeal symptoms were excluded, and no reactions required epinephrine. Children 
with a history of life-threatening reactions were excluded for safety.25 This group may be the 
most likely to undertake SLIT and achieve clinically significant results.
SLIT may ultimately represent a safer method of immunotherapy for patients with a history 
of severe allergy who cannot tolerate OIT, or as a bridge to OIT to decrease side effects and 
improve safety, but it may never be the most effective method to induce clinically significant 
desensitization or SU given the lower daily maintenance doses used. Further investigation 
into this possibility is needed as well as the duration of therapy required and any potential 
lasting effects of SLIT. Unfortunately, recently published follow-up data from the previously 
cited CoFAR SLIT study demonstrate substantial rates of nonadherence and lower rates of 
SU (10.8%) than seen in OIT.58 Given that indefinite exposure is likely necessary to 
maintain whatever treatment benefits are achieved, this is a concerning finding. Studies 
directly comparing SLIT and OIT are discussed in the next section.
Sublingual immunotherapy versus oral immunotherapy
In a DBPC pilot study comparing SLIT and OIT, 21 children with peanut allergy were 
randomized to receive active SLIT/placebo OIT or active OIT/placebo SLIT. Although 
adverse reactions and withdrawal were less common among the active SLIT group, reaction 
thresholds were significantly higher in the OIT group (141-versus 22-fold, P = .01), and 
SLIT overall was not significantly superior to placebo.59 A retrospective comparison was 
carried out among peanut-allergic subjects who had completed 2 years of therapy, with 23 
subjects in the OIT group and 27 subjects in the SLIT group. Safety was not directly 
compared, but the amount of peanut protein tolerated was higher in the OIT group and 
showed less variability, while changes in immunologic parameters (eg, IgE, IgG4, basophil 
reactivity) were greater in the OIT group.60
Another comparison of SLIT and OIT was performed for CM allergy as an open-label, 
randomized study. Thirty children were randomized to SLIT or SLIT converting to OIT at a 
lower and a higher dose, with a period off-therapy after about 15 months of maintenance in 
all groups. Adverse events led 2 children from the OIT group to withdraw. All children who 
reached maintenance were able to tolerate a higher amount of CM protein, and the amount 
increased with time. After 60 weeks, 60% of the SLIT group tolerated at least 10 times 
baseline CM protein, whereas 90% of the OIT group did the same, but this was not 
statistically significant (P = .053). After 6 weeks off therapy, only 1 in 10 children in the 
SLIT group maintained SU, whereas 8 of 20 in the OIT group had SU to CM, but again this 
was not significant (P = .09). Notably, 2 children reacted after only 1 week off therapy. 
Limitations to this study include small sample size and lack of power as well as lack of a 
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placebo group.61 These early results suggest that despite a poorer safety profile, OIT is more 
effective than SLIT in inducing desensitization.
Epicutaneous immunotherapy
EPIT is an alternative approach to oral methods that is performed by repeated application of 
an allergen to intact skin. This approach is accomplished through a novel and proprietary 
epicutaneous delivery system (EDS) successfully developed in animal models.62 The EDS 
uses a circular disc spray-dried with allergen. Perspiration solubilizes the allergen, which is 
then disseminated into the stratum corneum. Food EPIT is ongoing in phase 1 and 2 trials, 
and it is important to note that there are few peer-reviewed results published in the literature 
to date. Pilot studies have found that it is relatively well-tolerated with very few systemic 
reactions and no reports of anaphylaxis. Reactions are primarily mild, cutaneous symptoms, 
including erythema, pruritus, and flares of atopic dermatitis.6364
However, these studies have failed to show a statistically significant increase in the amount 
of food tolerated by milk- and peanut-allergic subjects treated with EPIT. The phase 1 CM 
EPIT pilot study was only performed for 3 months, which may not be long enough to show a 
significant effect. Nineteen subjects were randomized to milk EPIT (n = 10) or placebo (n = 
9), with OFC before and after the use of EPIT. The mean cumulative tolerated dose was 12-
fold higher in the active group versus 8% in the placebo, which was not statistically different 
(P = .13). Subjects in the active treatment group had a higher risk of local eczema at the site 
of antigen delivery. Interestingly, in one child, they observed a decrease in the minimum 
amount of CM protein that was tolerated after undergoing EPIT, compared with pre-EPIT 
CM OFC. 64 The potential for increased sensitization with cutaneous exposure is a concern 
with EPIT in light of the dual exposure hypothesis proposed by Lack.65 The hypothesis 
proposes that low-dose cutaneous exposure to a food can increase allergic sensitization, 
while oral/gastrointestinal exposure leads to tolerance.
The peanut EPIT pilot study followed children for 18 months of therapy and found a 
progressively increasing amount of peanut protein that was tolerated in the active group, but 
again it was not statistically significant.64 There are currently 3 clinical trials underway that 
will investigate various doses, safety, and efficacy, with 1 in Europe and 2 in the United 
States. If successful, these studies, and others performed for inhalant allergy, could suggest 
that EPIT may be a viable and safe treatment option for food allergy.
Nonspecific immunotherapy
Anti-Immunoglobulin E Therapy
Use of anti-IgE as monotherapy for food allergy was first investigated in a DBPC trial of the 
humanized, monoclonal, anti-IgE antibody TNX-901. Anti-IgE significantly increased 
reaction thresholds to peanut flour by 76% in the active group, although the trial was 
terminated early before completing subject recruitment.66 More recent phase I trials have 
used omalizumab as an adjunct to OIT, and these studies are discussed next. Subjects are 
generally pretreated with omalizumab for 2 to 5 months during a washout period and then 
continued on therapy until a maintenance dose of OIT is reached.
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A pilot study in 13 children with peanut allergy demonstrated that omalizumab in 
conjunction with peanut OIT was effective at decreasing initial reactions and allowed for a 
more rapid build-up phase, with 92% of children achieving maintenance. Reactions were 
rare and mild during the study; however, after omalizumab was stopped, half of the children 
experienced reactions, and 17% required epinephrine. Notably, this small sample of patients 
had an overall higher total and peanut-specific IgE level than many other OIT studies.67
CM OIT was studied with omalizumab in 11 patients. After a 9-week lead-in on 
omalizumab, they underwent rush CM desensitization. Reactions were again rare and 
relatively mild, with only 4 reactions requiring epinephrine, which is similar to other studies. 
Unlike in the peanut study, increased reactions were not experienced after stopping 
omalizumab. The study is limited by a small sample size and lack of placebo group, and 
baseline OFCs were not performed, so the significance in the amount of CM protein 
tolerated after OIT cannot be established.68
A larger, phase I study examined the use of omalizumab as an adjunct to multiple food OIT. 
Twenty-five subjects were desensitized to up to 5 different foods. Doses of each allergen 
were escalated until a maintenance dose of 4000 mg was reached. Reactions were 
experienced by 5.3% of subjects, and this rate decreased over time. No subjects had serious 
adverse events while on omalizumab, although one patient did have a serious reaction 
requiring epinephrine off omalizumab in the maintenance phase.69
These studies suggest that omalizumab may be useful as an adjunct to other forms of 
immunotherapy. Aside from being relatively safe and well tolerated, it confers several 
benefits over immunotherapy alone, including decreased initial reactions, shorter escalation 
phases, and more patients reaching higher cumulative doses during rush desensitization. 
However, further investigation is needed to identify the appropriate dose, duration of 
pretreatment, and optimal length of use during therapy. Omalizumab is currently only FDA-
approved in patients aged 12 years and older with severe atopic asthma or chronic idiopathic 
urticaria. The lack of a clinical indication for use in food allergy and cost has restricted its 
use to a research setting thus far.
Chinese Herbal Formula
Interest in complementary and alternative therapies and encouraging data from mouse 
models have led to clinical trials investigating the use of Chinese herbal therapy as a 
treatment of food allergy. Food allergy herbal formula-2 (FAHF-2), a compound containing 
9 different traditional Chinese herbs, has been shown to be safe in preclinical and pilot 
studies. Some efficacy was seen in food-allergic mice treated with FAHF-2.70 Preliminary 
results of phase 2 trials in humans reveal that the treatment is safe. However, at the dose 
used in this study, there was no statistically significant benefit observed in the treatment 
group. Notably, there was poor adherence among the treatment group given the large number 
of capsules required.71 The major advantage of this therapy is that it is nonspecific, and 
could, therefore, be used to treat individuals with multiple food allergies if efficacy can be 
demonstrated with other herbal formulations and dosing regiments that are in preclinical 
studies.70
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Table 3 provides an overview of the major forms of immunotherapy discussed earlier, with a 
summary of the advantages and disadvantages of each.
Probiotics
Probiotic supplementation has been examined in several allergic diseases, including asthma 
and atopic dermatitis, with mixed results. A recent meta-analysis including 21 studies found 
a significant decrease in the risk of atopic sensitization (positive skin prick test or elevated 
specific IgE) to common allergens, but not specifically to food. They found that prenatal and 
postnatal administration caused a significant reduction in sensitization. However, probiotics 
did not protect subjects from developing asthma or wheeze.72 Despite mixed results, 
probiotics remain an area of interest as a nonspecific form of immunotherapy.
One of the largest and most rigorous studies on probiotics was published in 2009, evaluating 
119 infants with CM allergy. This randomized, DBPC study demonstrated no increase in 
tolerance to CM after 6 months of probiotic supplementation.73 More recently, a study of 55 
infants with CM allergy was randomized to receive extensively hydrolyzed casein formula, 
with or without probiotic supplementation, for 6 months. They found statistically 
significantly higher rates of tolerance to CM at 6 and 12 months of therapy in the probiotic 
groups; however, greater differences were seen for those infants who had non-IgE-mediated 
allergy to CM.74 Probiotics have also been used as an adjunct to peanut OIT. A DBPC trial 
randomized 62 subjects with peanut allergy to receive probiotics plus peanut OIT (PPOIT) 
or placebo over an 18-month period. Maintenance therapy was then stopped for 2 to 5 
weeks, and subjects underwent an OFC. Possible SU was achieved in 82.1% receiving 
PPOIT and 3.6% receiving placebo (P <.001). Nine children would need to be treated for 7 
to achieve SU (1.27; 95% confidence interval, 1.06–1.59). Unfortunately, the PPOIT group 
was not compared with OIT alone, so it is impossible to determine the independent effect of 
probiotics.75 Carefully designed trials with appropriate controls are necessary for defining 
the effect of probiotic supplementation on food allergy.
Eosinophilic esophagitis and food immunotherapy
Although OIT has not been studied as a treatment of eosinophilic esophagitis (EoE) (rather, 
food avoidance is one treatment option), it deserves special consideration in the realm of 
OIT. The development of EoE has been observed in a small number of patients undergoing 
OIT for food allergy. Most of the current literature regarding this phenomenon consists of 
case reports and small case series. A recent systematic review with meta-analysis found one 
randomized clinical trial with 40 patients in which one child developed EoE. Three other 
full-length articles also met inclusion criteria, for a total of 6 of 179 patients developing EoE 
attributed to food OIT. According to their analysis, the incidence of EoE on OIT was 2.7%; 
however, they note considerable limitations. A significant drawback to these reports is that 
subjects are rarely screened for EoE before beginning clinical OIT trials due to the costs and 
risks associated with endoscopy. Given the frequency of comorbid IgE-mediated food 
allergy in patients with EoE, is it unclear whether the EoE was induced by OIT or existed as 
subclinical disease before treatment. Given available evidence, the risk of developing EoE 
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while on OIT should not preclude further investigation, but it should be recognized as a 
potential adverse outcome and monitored in clinical research trials.76
Despite this risk of EoE while undergoing food OIT, baked milk may be safe to include in 
the diets of children with concomitant CM allergy and EoE. A small retrospective study in 
children with EoE, without IgE-mediated food allergy, found that 73% of patients 
maintained histologic remission of EoE while eating 2 to 3 servings per week of baked milk 
for 6 weeks.77 It remains to be seen if the same is true for baked egg.
Failed methods of immunotherapy
Several additional methods have been attempted as food allergy therapy, with significant 
safety concerns or lack of efficacy. Given the effectiveness of subcutaneous immunotherapy 
(SCIT) in treating venom and environmental allergies, researchers hypothesized that 
subcutaneous injection of food antigens would yield similar results. In a study published in 
1997, peanut SCIT was performed in 12 patients. Although some efficacy was established, a 
high rate of systemic reactions prevented patients from reaching or continuing maintenance 
dosing. Following an anaphylaxis-related death of a patient who was mistakenly given a 
higher dose of peanut, it was concluded that peanut SCIT carried an unacceptable risk of 
severe reactions, preventing its continued clinical use.78
Escherichia coli (E-coli) encapsulated, recombinant Modified Peanut proteins Ara h 1, Ara h 
2, Ara h 3 (EMP-123). EMP-123 is a novel form of immunotherapy that has not progressed 
beyond phase 1 trials due to safety concerns. EMP-123 is a rectally administered peanut 
vaccine comprising 3 recombinant modified peanut antigens (Ara h 1, 2, and 3) encapsulated 
within heat/phenol-inactivated Escherichia coli. Although the vaccine was safe in healthy 
control subjects, peanut-allergic subjects experienced significant adverse events; half of the 
10 subjects terminated dosing early, and 2 suffered anaphylaxis requiring epinephrine.79 
Both of these studies are important for historical consideration as well as potential future use 
if adjunctive therapies prove to minimize adverse reactions.
Preclinical studies
In addition to the ongoing studies mentioned previously, a variety of potential methods of 
immunotherapy are in development and preclinical trials. A summary is included in Fig. 2. 
Some of these methods may represent promising future directions in food allergy, requiring 
continued rigorous investigation.
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* Can true immune tolerance be achieved through food desensitization?
* What is the preferred route for antigen administration?
* Do clinical outcomes improve if immunotherapy is started earlier in life?
* How long must therapy continue in order to achieve a permanent effect?
* What differences exist between children who naturally outgrow food 
sensitivity and those who are desensitized?
* Does immunotherapy hasten the development of immunologic tolerance in 
children who will ultimately outgrow a food allergy?
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* The standard of care for the management of food allergies is education, 
avoidance of trigger foods, and treatment of allergic reactions due to 
accidental ingestion.
Oral, sublingual, and epicutaneous immunotherapy are all investigational 
treatment modalities primarily performed in research settings.
* Evidence from clinical trials suggests that oral immunotherapy and possibly 
sublingual immunotherapy can effectively desensitize many subjects to 
trigger foods. A subset of desensitized subjects may achieve sustained 
unresponsiveness after withdrawal of therapy.
* Nonspecific immunotherapy and other emerging therapies using modified 
food antigens may also be options for treatment, but they are currently 
limited to early clinical or preclinical trials.
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* In an effort to answer these questions, researchers are now performing clinical trials in 
humans, predominantly with OIT, sublingual immunotherapy (SLIT), and epicutaneous 
immunotherapy (EPIT). It is important to note that these 3 most commonly considered 
methods of immunotherapy are allergen-specific, meaning that the therapy is only 
effective for the particular food given. Nonspecific therapies such as monoclonal 
antibodies to IgE have also been used to alter host immune responses. Second-generation 
OIT trials are beginning to use specific and nonspecific approaches in tandem to increase 
safety and efficacy.
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Immunotherapy for food allergy remains a promising area for future clinical application. 
Many of the questions posed by early investigators remain unanswered. Clinical trials 
have provided some insight as to viable treatment options for food allergy 
immunotherapy. At this point, the following conclusions can be made based on current 
evidence:
• Desensitization can be achieved in most subjects receiving OIT and 
SLIT. Among desensitized individuals, a small subset may achieve SU.
• Because of the absence of large controlled studies that include a natural 
history group, it cannot be definitively concluded that the number of 
subjects who achieve SU on OIT is greater than the number of 
individuals who would naturally outgrow their food allergy.
• When compared with OIT, SLIT offers an enhanced safety profile at 
the expense of decreased efficacy.
• Attempts at desensitization may be more effective and rapid if 
omalizumab is used as an adjunct.
• Adverse effect profiles for all forms of food allergy immunotherapy are 
still being characterized, because the population that may benefit most 
from these therapies (those with a history of severe anaphylaxis) has 
been excluded from nearly all studies. Potential links between OIT and 
the development of EoE also require further investigation.
Continued investigation may reveal that among the variety of methods, certain forms may 
be best suited for certain foods or subsets of patients with or without adjunctive therapy. 
Given outstanding questions regarding safety and efficacy, food allergy immunotherapy 
requires further investigation before incorporation into routine clinical practice.
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Approximate changes seen in immunologic parameters for food allergy while undergoing 
immunotherapy. Notably, basophil reactivity declines relatively quickly. IgG4 and IgE 
increase, although ultimately IgE will decrease. SPT, skin prick test.
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Many preclinical studies are in process as well as phase 2 trials as discussed. OIT will move 
into phase 3 trials. Other studies have not progressed beyond phase 1 studies due to safety or 
efficacy concerns. EMP-123, E-coli encapsulated, recombinant Modified Peanut proteins 
Ara h 1, Ara h 2, Ara h 3.
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Table 1
Early history of allergen immunotherapy for food allergy
Year Summary of Key Findings
1905
Finkelstein conceptualizes OIT. He successfully desensitizes nurslings with “milk idiosyncrasy” by gradually administering increasing 
drops of milk.15
1908
Schofield treats a 13-year-old patient with egg allergy over an 8-mo period by incrementally increasing small amounts of raw egg 
disguised in pill form.13
1912
Schloss describes a patient with allergies to egg, oat, and almond, which he orally desensitizes to egg. Sensitivity to almond and oat 
also decreases during this treatment. He uses skin testing to guide up-dosing during therapy.16
1920
Schloss reports 5 patients with egg allergy treated with subcutaneous injection of ovomucoid. He also describes 12 children with food 
allergies successfully desensitized using OIT.17
1920
Park describes oral desensitization of a child with hypersensitiveness to cow’s milk. Pallor and drowsiness were noted during build-up 
phase.18
1926
Stuart and Farnham advise treatment of food allergies by the oral method at an early age. In cases of milk or egg sensitization, their 
recommendation is enthusiastic because treatments are “simple and regularly successful.”19
1930
Freeman performs rush inoculation over 8 d with cod fish juices in a 7-y-old boy with fish sensitivity. The patient is subsequently 
started on a fish diet and prescribed an ounce of cod-liver oil daily. A concurrent egg allergy resolves with this therapy.20
1935
Keston, Waters, and Hopkins report effectively desensitizing 50 cases of food allergy to milk, wheat, egg, orange, tomato, or cocoa and 
publish oral desensitization protocols to each of these foods.21
1940 Edwards describes successful oral desensitization of 11 of 12 patients with milk allergy using protocols published by Keston et al.22
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Table 2
Overview of oral immunotherapy
Phase Length Description
Modified rush 1 d Minute quantities given and dose is escalated over a period of several hours (6–8 doses)
Build-up period 6–9 mo Daily doses taken at home with gradual increases performed under clinical observation every 1–2
Maintenance Months to years Target dose of allergen consumed daily at home


















• Can give larger maintenance 
doses (g) than SLIT/EPIT 
(mg)
• More effective than SLIT
• Greatest side effects
• Not tolerated in 15%–20% of subjects
• Potential for iatrogenic EoE
• Requires long-term adherence
SLIT
• Fewer side effects than OIT
• Not tolerated in 5% of 
subjects
• Only able to reach small maintenance 
doses (mg)
• Not as effective as OIT
• Requires long-term adherence
EPIT
• May have fewer side effects 
than SLIT and OIT
• May be safer in broader 
clinical settings
• Only able to reach small maintenance 
doses (mg)
• May only be as effective as SLIT, likely 
less than OIT








• Potentially desensitize to all 
food allergens
• May have the fewest side 
effects
• May have the poorest efficacy, potentially 
limiting use to adjunct therapy
• Omalizumab is not currently approved by 
the US FDA for food allergy and is cost-
prohibitive
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